{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T09:39:18Z","timestamp":1794649158863,"version":"4.9.1"},"reference-count":19,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T00:00:00Z","timestamp":1735776000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014387","name":"Acadia Pharmaceuticals Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014387","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.clinthera.2024.12.012","type":"journal-article","created":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T21:20:00Z","timestamp":1737062400000},"page":"181-188","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Assessing Experiences With Trofinetide for Rett Syndrome: Interviews With Caregivers of Participants in Clinical Trials"],"prefix":"10.1016","volume":"47","author":[{"given":"Amy M.","family":"Barrett","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oyebimpe","family":"Olayinka-Amao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dilesh","family":"Doshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathie M.","family":"Bishop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James M.","family":"Youakim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2024.12.012_bib0001","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/13810","article-title":"Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2","volume":"23","author":"Amir","year":"1999","journal-title":"Nat Genet"},{"key":"10.1016\/j.clinthera.2024.12.012_bib0002","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/j.1651-2227.1985.tb10993.x","article-title":"Rett's syndrome: prevalence and impact on progressive severe mental retardation in girls","volume":"74","author":"Hagberg","year":"1985","journal-title":"Acta Paediatr Scand"},{"key":"10.1016\/j.clinthera.2024.12.012_bib0003","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s13643-023-02169-6","article-title":"Global prevalence of Rett syndrome: systematic review and meta-analysis","volume":"12","author":"Petriti","year":"2023","journal-title":"Syst Rev"},{"key":"10.1016\/j.clinthera.2024.12.012_bib0004","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/1866-1955-6-20","article-title":"Developmental delay in Rett syndrome: data from the natural history study","volume":"6","author":"Neul","year":"2014","journal-title":"J Neurodev Disord"},{"key":"10.1016\/j.clinthera.2024.12.012_bib0005","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1002\/ana.22124","article-title":"Rett syndrome: revised diagnostic criteria and nomenclature","volume":"68","author":"Neul","year":"2010","journal-title":"Ann Neurol"},{"key":"10.1016\/j.clinthera.2024.12.012_bib0006","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.pediatrneurol.2015.06.003","article-title":"The changing face of survival in Rett syndrome and MECP2-related disorders","volume":"53","author":"Tarquinio","year":"2015","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.clinthera.2024.12.012_bib0007","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1038\/s41591-023-02398-1","article-title":"Trofinetide for the treatment of Rett syndrome: a randomized phase 3 study","volume":"29","author":"Neul","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.clinthera.2024.12.012_bib0008","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1016\/j.medj.2024.05.018","article-title":"Trofinetide for the treatment of Rett syndrome: results from the open-label extension LILAC study","volume":"5","author":"Percy","year":"2024","journal-title":"Med"},{"key":"10.1016\/j.clinthera.2024.12.012_bib0009","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/j.medj.2024.06.007","article-title":"Trofinetide for the treatment of Rett syndrome: long-term safety and efficacy results from the open-label LILAC-2 study","volume":"5","author":"Percy","year":"2024","journal-title":"Med"},{"key":"10.1016\/j.clinthera.2024.12.012_bib0010","unstructured":"Percy AK, Ryther R, Marsh ED, et al. Trofinetide for the treatment of girls aged two to four years with Rett syndrome: final results from the open-label DAFFODIL study. Presented at: American Academy of Neurology 2024 Annual Meeting; April 13-18, 2024; Denver, CO."},{"key":"10.1016\/j.clinthera.2024.12.012_bib0011","unstructured":"US Food and Drug Administration. Patient-focused drug development: collecting comprehensive and representative input. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/patient-focused-drug-development-collecting-comprehensive-and-representative-input. Accessed May 7, 2024."},{"key":"10.1016\/j.clinthera.2024.12.012_bib0012","unstructured":"US Food and Drug Administration. Patient-focused drug development: methods to identify what is important to patients: guidance for industry, Food and Drug Administration staff, and other stakeholders. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/patient-focused-drug-development-methods-identify-what-important-patients. Accessed May 7, 2024."},{"key":"10.1016\/j.clinthera.2024.12.012_bib0013","unstructured":"US Food and Drug Administration. Rare diseases: considerations for the development of drugs and biological products. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/rare-diseases-considerations-development-drugs-and-biological-products. Accessed May 7, 2024."},{"key":"10.1016\/j.clinthera.2024.12.012_bib0014","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.pediatrneurol.2017.07.002","article-title":"A double-blind, randomized, placebo-controlled clinical study of trofinetide in the treatment of Rett syndrome","volume":"76","author":"Glaze","year":"2017","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.clinthera.2024.12.012_bib0015","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s11689-023-09502-z","article-title":"Top caregiver concerns in Rett syndrome and related disorders: data from the US natural history study","volume":"15","author":"Neul","year":"2023","journal-title":"J Neurodev Disord"},{"key":"10.1016\/j.clinthera.2024.12.012_bib0016","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1177\/08830738231172066","article-title":"Meaningful improvements in Rett syndrome: a qualitative study of caregivers","volume":"38","author":"McGraw","year":"2023","journal-title":"J Child Neurol"},{"key":"10.1016\/j.clinthera.2024.12.012_bib0017","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1111\/1469-7610.00236","article-title":"The Rett Syndrome Behaviour Questionnaire (RSBQ): refining the behavioural phenotype of Rett syndrome","volume":"43","author":"Mount","year":"2002","journal-title":"J Child Psychol Psychiatry"},{"key":"10.1016\/j.clinthera.2024.12.012_bib0018","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1191\/1478088706qp063oa","article-title":"Using thematic analysis in psychology","volume":"3","author":"Braun","year":"2006","journal-title":"Qual Res Psychol"},{"key":"10.1016\/j.clinthera.2024.12.012_bib0019","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1023\/A:1020909529486","article-title":"A purposeful approach to the constant comparative method in the analysis of qualitative interviews","volume":"36","author":"Boeije","year":"2002","journal-title":"Qual Quant"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291824004168?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291824004168?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T12:48:34Z","timestamp":1740401314000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291824004168"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":19,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S0149291824004168"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2024.12.012","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Assessing Experiences With Trofinetide for Rett Syndrome: Interviews With Caregivers of Participants in Clinical Trials","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2024.12.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}